Does your state have enough testing capacity to re-open? And which states should consider re-opening first? No, it’s not Georgia – don’t even think about it. We called and identified 1300+ CLIA labs that do molecular testing – mostly located at US hospitals – with 2728 instruments that have the throughput capacity to run just under 1,000,0000 tests per day.
The worldwide COVID-19 crisis has spawned hundreds of diagnostic testing kits and daily announcements. How do you sort out the significant tests with large distribution and market share from promising startups or low volume companies? This Kalorama COVID-19 IVD Test Tracker will update on new EUAs with information and analysis from Kalorama analysts and will be updated on a regular basis.
This map represents national and local hospitals and medical facility locations with installed molecular equipment by manufacturer.
Our COVID-19 Clinical Masterfile is a cut of our Kalorama Clinical Masterfile of 43,000 diagnostics instruments.
A bi-weekly clinical lab tracker is conducted over 48 hours every other Friday/Saturday; US clinical and diagnostics labs answer questions regarding the impact of COVID-19 on their laboratories.
Social distancing and the crisis surrounding the COVID-19 epidemic has lead to an increase in the use of telehealth devices. Kalorama has reported on telehealth markets for a decade. Our analysts have reviewed companies in the field and contacted companies for their business status and has observed the following recent trends.
For years, Kalorama Information has covered the fields of molecular diagnostics, immunoassays, vaccines and telehealth. These areas are both sought-after and challenged during the current COVID-19 crisis. This report provides trending developments, company announcements and analysis from the Kalorama analysis team on the fast-breaking events in the COVID-19 pandemic.
Kalorama COVID-19 Update: Molecular Diagnostics, Immunoassays, Vaccines, Telehealth and Other Areas
The vaccine market is poised for a rather substantial increase in the next five years due to the number of vaccines in development and the push for a COVID-19 vaccine. As the COVID-19 outbreak advanced worldwide, companies stepped up to the challenge, scrambling to provide a potential vaccine. This report examines the market for human vaccines used to prevent various types of disease, focusing on commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable, with a discussion of the demanding tasks that are facing vaccine manufacturers.
Vaccine Development and Production Trends, COVID-19 and Other Vaccines Pipeline